Raymond James & Associates’s PTC Therapeutics PTCT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | $342K | Buy |
+9,219
| New | +$342K | ﹤0.01% | 3314 |
|
|
2023
Q2 | – | Sell |
-5,183
| Closed | -$251K | – | 3869 |
|
|
2023
Q1 | $251K | Sell |
5,183
-2,849
| -35% | -$138K | ﹤0.01% | 3330 |
|
|
2022
Q4 | $307K | Buy |
8,032
+2,863
| +55% | +$109K | ﹤0.01% | 3184 |
|
|
2022
Q3 | $259K | Buy |
5,169
+13
| +0.3% | +$651 | ﹤0.01% | 3258 |
|
|
2022
Q2 | $207K | Sell |
5,156
-3,185
| -38% | -$128K | ﹤0.01% | 3469 |
|
|
2022
Q1 | $311K | Buy |
8,341
+1,243
| +18% | +$46.3K | ﹤0.01% | 3363 |
|
|
2021
Q4 | $283K | Sell |
7,098
-27
| -0.4% | -$1.08K | ﹤0.01% | 3454 |
|
|
2021
Q3 | $265K | Buy |
7,125
+311
| +5% | +$11.6K | ﹤0.01% | 3479 |
|
|
2021
Q2 | $288K | Sell |
6,814
-6,650
| -49% | -$281K | ﹤0.01% | 3439 |
|
|
2021
Q1 | $638K | Buy |
13,464
+3
| +0% | +$142 | ﹤0.01% | 2821 |
|
|
2020
Q4 | $822K | Sell |
13,461
-7,763
| -37% | -$474K | ﹤0.01% | 2456 |
|
|
2020
Q3 | $992K | Buy |
21,224
+940
| +5% | +$43.9K | ﹤0.01% | 2181 |
|
|
2020
Q2 | $1.03M | Buy |
20,284
+6,329
| +45% | +$321K | ﹤0.01% | 2138 |
|
|
2020
Q1 | $623K | Buy |
13,955
+6,887
| +97% | +$307K | ﹤0.01% | 2263 |
|
|
2019
Q4 | $339K | Buy |
7,068
+43
| +0.6% | +$2.06K | ﹤0.01% | 2991 |
|
|
2019
Q3 | $238K | Sell |
7,025
-4,197
| -37% | -$142K | ﹤0.01% | 3131 |
|
|
2019
Q2 | $505K | Buy |
11,222
+3,837
| +52% | +$173K | ﹤0.01% | 2647 |
|
|
2019
Q1 | $278K | Hold |
7,385
| – | – | ﹤0.01% | 3008 |
|
|
2018
Q4 | $253K | Buy |
+7,385
| New | +$253K | ﹤0.01% | 2963 |
|
|
2016
Q1 | – | Sell |
-54,660
| Closed | -$1.77M | – | 2852 |
|
|
2015
Q4 | $1.77M | Sell |
54,660
-10,212
| -16% | -$331K | 0.01% | 1336 |
|
|
2015
Q3 | $1.73M | Buy |
+64,872
| New | +$1.73M | 0.01% | 1299 |
|